Research programme: RS7-based monoclonal antibodies - Immunomedics

Drug Profile

Research programme: RS7-based monoclonal antibodies - Immunomedics

Alternative Names: 1R-(E1)-(E1) antibody; 22-Rap; E1-L-thP1; E1-Rap; hRS7-Ranpirnase; hRS7-Rap; hRS7-Rap immunotoxin; Humanised monoclonal antibody RS7; Humanised RS7; IMMU 112; IMMU 112 I-131; Monoclonal antibody RS7

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Camptothecins; Monoclonal antibodies; Ribonucleases
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 24 Nov 2016 Programme is still in preclinical phase for solid tumours in USA
  • 15 Nov 2016 IBC Pharmaceuticals receives patent allowance for Dock-and-Lock (DNL) technology, for delivery of interference RNA, in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top